Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, Tasmania 7170, Australia.
Mar Drugs. 2011;9(10):1731-1760. doi: 10.3390/md9101731. Epub 2011 Sep 30.
Published research on fucoidans increased three fold between 2000 and 2010. These algal derived marine carbohydrate polymers present numerous valuable bioactivities. This review discusses the role for fucoidan in the control of acute and chronic inflammation via selectin blockade, enzyme inhibition and inhibiting the complement cascade. The recent data on toxicology and uptake of fucoidan is detailed together with a discussion on the comparative activities of fractions of fucoidan from different sources. Recent in vivo, in vitro and clinical research related to diverse clinical needs is discussed. Targets include osteoarthritis, kidney and liver disease, neglected infectious diseases, hemopoietic stem cell modulation, protection from radiation damage and treatments for snake envenomation. In recent years, the production of well characterized reproducible fucoidan fractions on a commercial scale has become possible making therapies from fucoidan a realizable goal.
2000 年至 2010 年期间，有关褐藻胶的已发表研究增加了两倍。这些源自藻类的海洋碳水化合物聚合物具有多种有价值的生物活性。本文讨论了褐藻胶通过选择素阻断、酶抑制和抑制补体级联反应来控制急性和慢性炎症的作用。详细介绍了褐藻胶的毒理学和摄取的最新数据，并讨论了来自不同来源的褐藻胶级分的比较活性。讨论了与各种临床需求相关的最近的体内、体外和临床研究。目标包括骨关节炎、肾脏和肝脏疾病、被忽视的传染病、造血干细胞调节、辐射损伤保护以及蛇咬伤治疗。近年来，在商业规模上生产具有良好特征和可重现性的褐藻胶级分已成为可能，使褐藻胶疗法成为一个可行的目标。
